Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PAN Gene Mutation”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Early research (Phase 1)Looking for participantsNCT07458347
What this trial is testing

Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Who this might be right for
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc. 145
Testing effectiveness (Phase 2)WithdrawnNCT05041972
What this trial is testing

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Who this might be right for
HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
Ambrx, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06973564
What this trial is testing

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Who this might be right for
Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd. 294
Early research (Phase 1)Looking for participantsNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Study completedNCT01520870
What this trial is testing

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Who this might be right for
GlioblastomaBrain Tumor, Recurrent
Grupo Español de Investigación en Neurooncología 49
Testing effectiveness (Phase 2)Looking for participantsNCT06959615
What this trial is testing

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Who this might be right for
Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd. 334
Not applicableLooking for participantsNCT06008392
What this trial is testing

INTERogating Cancer for Etiology, Prevention and Therapy Navigation

Who this might be right for
CancerCancer Gene MutationPAN Gene Mutation+2 more
Mayo Clinic 500
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07629960
What this trial is testing

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more
Blueprint Medicines Corporation 265
Not applicableWithdrawnNCT01888562
What this trial is testing

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Who this might be right for
Endometrial Neoplasms
Washington University School of Medicine
Early research (Phase 1)UnknownNCT06078800
What this trial is testing

YL-17231 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 80
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Not applicableApproved For MarketingNCT05760586
What this trial is testing

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Who this might be right for
Low-grade Glioma
Day One Biopharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07640295
What this trial is testing

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Who this might be right for
Metastatic Pancreatic Ductal Adenocarcinoma
Jacobio Pharmaceuticals Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT02979821
What this trial is testing

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Who this might be right for
HER2 Gene MutationAdenocarcinoma Lung Stage IV
Korean Association for the Study of Targeted Therapy 6
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Next Page